111 related articles for article (PubMed ID: 11383627)
21. Blood glucose lowering and toxicological effects of zinc (II) complexes with maltol, threonine, and picolinic acid.
Kojima Y; Yoshikawa Y; Ueda E; Kondo M; Takahashi S; Matsukura T; Sakurai H; Hiroi T; Imaoka S; Funae Y
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):91-104. PubMed ID: 15080500
[TBL] [Abstract][Full Text] [Related]
22. Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes.
Kawabe K; Yoshikawa Y; Adachi Y; Sakurai H
Life Sci; 2006 May; 78(24):2860-6. PubMed ID: 16337244
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, structure analysis, solution chemistry, and in vitro insulinomimetic activity of novel oxovanadium(IV) complexes with tripodal ligands containing an imidazole group derived from amino acids.
Kawabe K; Sasagawa T; Yoshikawa Y; Ichimura A; Kumekawa K; Yanagihara N; Takino T; Sakurai H; Kojima Y
J Biol Inorg Chem; 2003 Nov; 8(8):893-906. PubMed ID: 14551811
[TBL] [Abstract][Full Text] [Related]
24. Anti-diabetes effect of Zn(II)/carnitine complex by oral administration.
Yoshikawa Y; Ueda E; Sakurai H; Kojima Y
Chem Pharm Bull (Tokyo); 2003 Feb; 51(2):230-1. PubMed ID: 12576666
[TBL] [Abstract][Full Text] [Related]
25. Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV).
Sakurai H; Fujii K; Watanabe H; Tamura H
Biochem Biophys Res Commun; 1995 Sep; 214(3):1095-101. PubMed ID: 7575515
[TBL] [Abstract][Full Text] [Related]
26. Insulinomimetic Zn complex (Zn(opt)2) enhances insulin signaling pathway in 3T3-L1 adipocytes.
Basuki W; Hiromura M; Sakurai H
J Inorg Biochem; 2007 Apr; 101(4):692-9. PubMed ID: 17316811
[TBL] [Abstract][Full Text] [Related]
27. A [meso-tetrakis(4-sulfonatophenyl)porphyrinato]zinc(ii) complex as an oral therapeutic for the treatment of type 2 diabetic KKA(y) mice.
Saha TK; Yoshikawa Y; Sakurai H
ChemMedChem; 2007 Feb; 2(2):218-25. PubMed ID: 17245806
[TBL] [Abstract][Full Text] [Related]
28. Anti-Diabetic Effect of Organo-Chalcogen (Sulfur and Selenium) Zinc Complexes with Hydroxy-Pyrone Derivatives on Leptin-Deficient Type 2 Diabetes Model ob/ob Mice.
Nishiguchi T; Yoshikawa Y; Yasui H
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29215553
[TBL] [Abstract][Full Text] [Related]
29. Bis(allixinato)oxovanadium(IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrone-vanadium complexes.
Adachi Y; Yoshida J; Kodera Y; Katoh A; Takada J; Sakurai H
J Med Chem; 2006 Jun; 49(11):3251-6. PubMed ID: 16722643
[TBL] [Abstract][Full Text] [Related]
30. [Development research of new Zn complexes with anti-diabetic effect--structure-activity-related studies by displacement of coordination atom].
Yoshikawa Y
Yakugaku Zasshi; 2012; 132(9):1051-5. PubMed ID: 23023423
[TBL] [Abstract][Full Text] [Related]
31. Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.
Young PW; Cawthorne MA; Coyle PJ; Holder JC; Holman GD; Kozka IJ; Kirkham DM; Lister CA; Smith SA
Diabetes; 1995 Sep; 44(9):1087-92. PubMed ID: 7657033
[TBL] [Abstract][Full Text] [Related]
32. Anti-hyperglycemic Effect of Long-Term Bis(hinokitiolato)zinc Complex ([Zn(hkt)
Naito Y; Yoshikawa Y; Shintani M; Kamoshida S; Kajiwara N; Yasui H
Biol Pharm Bull; 2017; 40(3):318-326. PubMed ID: 28250273
[TBL] [Abstract][Full Text] [Related]
33. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of Type II diabetes.
Reed MJ; Meszaros K; Entes LJ; Claypool MD; Pinkett JG; Brignetti D; Luo J; Khandwala A; Reaven GM
Diabetologia; 1999 Jan; 42(1):102-6. PubMed ID: 10027587
[TBL] [Abstract][Full Text] [Related]
34. Development of a novel antidiabetic zinc complex with an organoselenium ligand at the lowest dosage in KK-A(y) mice.
Fujimoto S; Yasui H; Yoshikawa Y
J Inorg Biochem; 2013 Apr; 121():10-5. PubMed ID: 23314593
[TBL] [Abstract][Full Text] [Related]
35. Investigating the target organs of novel anti-diabetic zinc complexes with organo‑selenium ligands.
Nishiguchi T; Yoshikawa Y; Yasui H
J Inorg Biochem; 2018 Aug; 185():103-112. PubMed ID: 29843022
[TBL] [Abstract][Full Text] [Related]
36. Antidiabetic copper(II)-picolinate: impact of the first transition metal in the metallopicolinate complexes.
Yasumatsu N; Yoshikawa Y; Adachi Y; Sakurai H
Bioorg Med Chem; 2007 Jul; 15(14):4917-22. PubMed ID: 17531495
[TBL] [Abstract][Full Text] [Related]
37. In vitro study of the insulin-like action of vanadyl-pyrone and -pyridinone complexes with a VO(O4) coordination mode.
Rangel M; Tamura A; Fukushima C; Sakurai H
J Biol Inorg Chem; 2001 Feb; 6(2):128-32. PubMed ID: 11293405
[TBL] [Abstract][Full Text] [Related]
38. Antidiabetic effects of flavonoids from Sophora flavescens EtOAc extract in type 2 diabetic KK-ay mice.
Yang X; Yang J; Xu C; Huang M; Zhou Q; Lv J; Ma X; Ke C; Ye Y; Shu G; Zhao P
J Ethnopharmacol; 2015 Aug; 171():161-70. PubMed ID: 26051831
[TBL] [Abstract][Full Text] [Related]
39. Metallokinetic study of zinc in the blood of normal rats given insulinomimetic zinc(II) complexes and improvement of diabetes mellitus in type 2 diabetic GK rats by their oral administration.
Fugono J; Fujimoto K; Yasui H; Kawabe K; Yoshikawa Y; Kojima Y; Sakurai H
Drug Metab Pharmacokinet; 2002; 17(4):340-7. PubMed ID: 15618684
[TBL] [Abstract][Full Text] [Related]
40. Challenge of studies on the development of new Zn complexes (Zn(opt)₂) to treat diabetes mellitus.
Yoshikawa Y; Murayama A; Adachi Y; Sakurai H; Yasui H
Metallomics; 2011 Jul; 3(7):686-92. PubMed ID: 21584335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
